An AI biotech emerges from stealth promis­ing drugs 'on de­mand.' What will that look like, and is it even pos­si­ble?

The newest AI and ma­chine learn­ing biotech launched Tues­day morn­ing, and it’s promis­ing some big things. But can the com­pa­ny de­liv­er?

Crey­on Bio emerged from stealth with $40 mil­lion in seed and Se­ries A fi­nanc­ing, the com­pa­ny said, with the goal of de­liv­er­ing pre­ci­sion med­i­cines “on de­mand” once its plat­form is ful­ly re­al­ized. The biotech wants to fo­cus on both rare and com­mon dis­eases, though it’s not spec­i­fy­ing which ones, and de­vel­op oligonu­cleotide-based med­i­cines that can work with any modal­i­ty, be it an­ti­sense, siR­NA or DNA and RNA edit­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER